Market Intelligence, Clinical Progress, and High-Purity Reagents for Acute Myeloid Leukemia (AML) and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for B23/NPM1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutants) | B23/NPM1 wild-type and Type A (NPM1c), Type B, Type C mutant recombinant proteins. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View B23/NPM1 Products |
| Gene Delivery | NPM1 WT and mutant (Type A/B/C) ORF lentivirus premade particles. Full-length ORF for stable AML cell line engineering. | View B23/NPM1 Products |
| Benchmark Antibody | Anti-B23/NPM1 recombinant antibody (mutation-specific). Chimeric framework; Sequence Verified. For screening and benchmark assay development. | View B23/NPM1 Products |
| Validator | NPM1 siRNA Set (3 unique sequences). For knockdown verification and assay specificity controls. | View B23/NPM1 Products |
| Related Target: MEN1 | Menin (MEN1). Synergistic pathway; menin inhibitors are in Phase III for NPM1-mutant AML. | View MEN1 Products |
| Related Target: XPO1 | Exportin-1 (XPO1). Nuclear export mechanism mediator for B23 mislocalization; combination therapy target. | View XPO1 Products |
| Related Target: FLT3 | FLT3 (CD135). Frequently co-mutated with NPM1 in AML; drives resistance; requires parallel counter-screening. | View FLT3 Products |
| Related Target: MDM2 | MDM2 (HDM2). MDM2 inhibitors synergize with NPM1-mutant strategies in TP53 wild-type AML. | View MDM2 Products |
| Related Target: IDH1 | IDH1. Epigenetic modifier; synergistic pathway in AML classification; common co-mutation. | View IDH1 Products |
| Related Target: TP53 | TP53 (p53). Direct binding partner; NPM1 regulates p53 stability and localization. | View TP53 Products |
| Related Target: KMT2A | KMT2A (MLL1). Forms complex with Menin; essential for downstream oncogene transcription in AML. | View KMT2A Products |
Critical Assay Challenges & TarMart Advantage
| Challenge | TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. Wild-Type Selectivity | Sequence-verified NPM1 Type A/B/C mutants and WT proteins (>95% purity, Mass spec confirmed) for direct SPR/BLI/ITC counter-screening. |
| Protein-Protein Interaction (PPI) Profiling | High-purity recombinant Menin/NPM1 and NPM1/TP53 proteins for TR-FRET or FP assay development. |
| Pentamerization/Oligomerization Studies | High-purity monomeric protein (HEK293 expressed) for native complex assembly and DLS validation. |
| Nuclear vs. Cytoplasmic Localization | Lentivirus-delivered ORF with C-terminal tags for stable cell line construction; enables live-cell imaging and fractionation assays. |
| Subfamily Counter-Screening (NPM2/NPM3) | NPM2 and NPM3 paralog proteins available with strict sequence verification to assess off-target liability. |
| Lack of Controls / False Positives | Clinical benchmark antibodies and validated siRNA sets included for specificity checks and knockdown validation. |
| High-concentration Biophysical Characterization | Endotoxin <1 EU/µg, HEK293 expressed; suitable for SPR, ITC, and thermal shift assays. |
Live B23/NPM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for B23/NPM1 therapeutics is intensifying, with major players shifting focus from indirect inhibitors (targeting the Menin-MLL interaction) to direct mutant NPM1 (NPM1c) targeted degraders, nuclear import inhibitors, and TCR-T therapies. As first-generation Menin inhibitors (e.g., revumenib, ziftomenib) reach advanced clinical stages for NPM1-mutated AML, the next wave of R&D is targeting the specific cytoplasmic mislocalization mechanisms of NPM1c, aiming to restore normal nucleolar function or induce mutant-specific degradation without disrupting essential wild-type B23. Combination regimens with FLT3 inhibitors, IDH inhibitors, and BCL-2 inhibitors are becoming standard, and targeting co-occurring mutations (e.g., FLT3-ITD, IDH1) drives the need for multi-target cell models and high-quality recombinant proteins for assay development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Menin Inhibitors) | Syndax, Kura Oncology, Biomea Fusion, Daiichi Sankyo | AML (NPM1-mutated) | PPI inhibition assay (high-purity Menin/NPM1 proteins needed) |
| Small Molecule (Nuclear Import Inhibitors) | Ascentage Pharma, Academic Consortia | AML (NPM1-mutated) | Mutant vs WT selectivity assay (purified mutant and WT proteins) |
| Targeted Degraders (PROTACs/Molecular Glue) | Arvinas, Cedilla Therapeutics, Emerging Biotechs | Refractory AML, High-risk AML | Pentamer disruption assay; selectivity assay with mutant vs WT proteins; TP53 interaction assay |
| XPO1 Inhibitor | Karyopharm (selinexor) | Relapsed AML | Combination synergy studies (NPM1 + XPO1 protein pairs) |
| Epigenetic Combinations | Daiichi Sankyo, Novartis | NPM1/FLT3 Co-mutant AML | Dual-target cell lines (NPM1 mutant + FLT3-ITD lentivirus co-transduction) |
| TCR-T / Immunotherapy | Zelluna, Medigene | Hematological Malignancies | HLA-peptide validation (strictly sequence-verified antigens needed) |